Care Access, a global health research company, has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to enhance vaccine and treatment accessibility for underserved and hard-to-reach communities during public health emergencies.
Care Access’s decentralized clinical trial network will be employed to establish a nationally representative network of community-based clinicians, foster partnerships with organizations in underserved areas, and collaborate with large-scale, long-term care providers. This network aims to overcome these communities’ barriers to obtaining life-saving medical interventions.
The partnership supports Care Access’s decentralized clinical research infrastructure, ensuring the rapid implementation of novel medical advancements during emergencies. The company’s experience conducting decentralized trials, including successfully enrolling over 1,000 participants from long-term care facilities during the COVID-19 pandemic, underscores the need for accessible clinical studies in remote and diverse locations.
Care Access CEO Ahmad Namvargolian indicated they aim to enhance decentralized clinical trial capabilities and serve harder-to-reach communities. The collaboration invests in the well-being of those who have historically faced obstacles in accessing health research.
Care Access will use the funds to expand its partner network, reaching underserved communities and ensuring equitable access to life-saving immunizations and treatments during public health emergencies. By leveraging its global network of research sites, Care Access will support the acceleration of medical advancements and improve the health outcomes of vulnerable populations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
